Search results for "CSC"

showing 10 items of 192 documents

Implication du récepteur 5-HT4 cardiaque humain dans la fibrillation auriculaire : rôle d’auto-anticorps dirigés contre ce récepteur ?

2004

The human cardiac 5-HT4 receptor was cloned in 1997. It is functional only in atrial myocytes where it is positively coupled via Gs to the adenylate cyclase, activates the cAMP-dependent protein kinase (PKA) and in consequence phosphorylates a variety of intracellular proteins implicated in excitation-contraction coupling. A number of studies suggest a role for the 5-HT4 receptor in the maintenance or elongation of atrial fibrillation. It is now accepted that certain cardiac pathologies involve auto-immune processes. Antibodies directed against the second extracellular loop of a number of cardiac G-protein linked receptors have been found. The human cardiac 5-HT4 receptor could therefore al…

human atrial myocytesantibodyreceptorfibrillation auriculaireanticorpssérotonineatrial fibrillation[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmyocytes atriaux humainsrécepteur[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemserotonin
researchProduct

The iron-regulatory hormone hepcidin: A possible therapeutic target?

2015

The maintenance of stable extracellular and intracellular iron concentrations requires the coordinated regulation of iron transport into plasma. Iron is a fundamental cofactor for several enzymes involved in oxidation-reduction reactions. The redox ability of iron can lead to the production of oxygen free radicals, which can damage various cellular components. Therefore, the appropriate regulation of systemic iron homeostasis is decisive in vital processes. Hepcidin has emerged as the central regulatory molecule of systemic iron homeostasis. It is synthesized in hepatocytes and in other cells and released into the circulation. It inhibits the release of iron from enterocytes of the duodenum…

inorganic chemicalscongenital hereditary and neonatal diseases and abnormalitiesIronFerroportinRegulatorInflammationdigestive system03 medical and health sciences0302 clinical medicineHepcidins[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHepcidinhemic and lymphatic diseasesmedicineExtracellularAnimalsHumansPharmacology (medical)Cation Transport ProteinsComputingMilieux_MISCELLANEOUS030304 developmental biologyPharmacology0303 health sciencesbiologyChemistrynutritional and metabolic diseasesMetabolism[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthLiverBiochemistryCardiovascular DiseasesCytoprotection030220 oncology & carcinogenesisbiology.proteinmedicine.symptomIntracellularHomeostasis
researchProduct

Organisaation laajuiset tietojärjestelmät : Valmet Oyj Rautpohjan yleiskustannusten budjetointi vuosina 1995-1996

1998

koordinaatioteoriabudjetointiODSSorganisaation päätöksentekoprosessitCSCW
researchProduct

A study of the relationship between regulatory systems, assessment e locomotion, and online learning groups

2011

The present paper examines the relationship between assessment, locomotion and attitudes and learning outcomes in a Computer-supported collaborative learning (CSCL) framework. Results showed that regulatory mode predicted exam marks, numbers of tasks completed, messages sent and attitudes towards the course and the ingroup. The theoretical implications and some reflections about CSCL and Regulatory-mode Theory (RMT) are presented.

lcsh:Theory and practice of educationCSCL3304CSCL Regulatory-mode theory higher education assessment locomotion.higher educationassessmentlocomotion.Computer Science Applications1707 Computer Vision and Pattern RecognitionRegulatory-mode theorySettore M-PSI/05 - Psicologia SocialeLocomotionlcsh:LB5-3640
researchProduct

Treatment of pulmonary embolism.

2015

International audience; The treatment of pulmonary embolism is going to be deeply modified by the development of Direct Oral Anticoagulants (DOACs). There are currently three anti-Xa factors (rivaroxaban, apixaban, edoxaban) and one anti-IIa factor (dabigatran) labeled by the FDA and the EMA. All these drugs are direct anticoagulant, orally effective, without the need for adaptation to hemostasis test. As kidney excretion is involved for all of them, they are contra-indicated in patients with severe renal failure (creatinine clearance<30mL/min according to Cockcroft & Gault formula). All the anti-Xa factor drugs are metabolized by liver cytochromes and then contra-indicated in case of liver…

medicine.drug_classPyridinesPyridones[SDV]Life Sciences [q-bio]PopulationRenal functionRisk AssessmentAntithrombinsDabigatranchemistry.chemical_compoundRivaroxaban[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemEdoxaban[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineHumanseducationeducation.field_of_studyRivaroxabanClinical Trials as Topic[ SDV ] Life Sciences [q-bio]business.industryMedicine (all)AnticoagulantGeneral MedicineVenous Thromboembolism[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.disease3. Good healthPulmonary embolismDabigatranThiazolesAntithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism; Medicine (all)chemistryAnesthesiaPyrazolesApixabanbusinessPulmonary Embolism[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drugFactor Xa Inhibitors
researchProduct

0134 : Atrial fibrillation is associated with a marker of endothelial function and oxidative stress in patients with acute myocardial infarction

2016

Background Atrial fibrillation (AF), whether silent or symptomatic, is a frequent and severe complication of acute myocardial infarction (AMI). Asymmetric dimethylarginine (ADMA), an endogenous eNOS inhibitor, is a risk factor for endothelial dysfunction. We addressed the relationship between ADMA plasma levels and AF occurrence in AMI. Methods 273 patients hospitalized for AMI were included. Continuous electrocardiographic monitoring (CEM) e48 hours was recorded and ADMA was measured by High Performance Liquid Chromatography on admission blood sample. Results The incidence of silent and symptomatic AF was 39(14%) and 29 (11%), respectively. AF patients were markedly older than patients wit…

medicine.medical_specialty030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineHeart ratemedicine030212 general & internal medicineMyocardial infarctionEndothelial dysfunctionRisk factorComputingMilieux_MISCELLANEOUSEjection fractionbusiness.industryIncidence (epidemiology)Atrial fibrillationEndothelial function[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseAtrial fibrillation3. Good healthMyocardial infarctionchemistryCardiologyCardiology and Cardiovascular MedicineAsymmetric dimethylargininebusiness
researchProduct

0135 : New regulators of iron metabolism, hepcidin and erythroferrone, in acute myocardial infarction

2016

Background Dysfunctional iron storage and transport are common in patients with chronic heart failure and associated with poor prognosis. Body iron could contribute to the pathogenesis of coronary artery disease (CAD) through its ability to induce oxidative stress. However, studies on the relationship between iron metabolism and CAD have yielded conflicting results. Patients and methods from the obseRvatoire des Infarctus de Cote d’Or (RICO) survey, 31 consecutive patients admitted in Intensive Care Unit for a first AMI were included. Serum concentrations of iron, transferrin, ferritin, the iron-regulatory hormone hepcidin and erythroferrone (a new hepcidinregulating hormone), transferrin s…

medicine.medical_specialty030204 cardiovascular system & hematologyHematocrit03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHepcidinTotal iron-binding capacityInternal medicineerythroferroneMedicine030212 general & internal medicineMyocardial infarctionComputingMilieux_MISCELLANEOUSchemistry.chemical_classificationbiologymedicine.diagnostic_testbusiness.industryTransferrin saturationErythroferrone[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.disease3. Good healthFerritinEndocrinologychemistryTransferrinbiology.proteinhepcidinbusinessCardiology and Cardiovascular Medicine
researchProduct

0127: Atrial fibrillation is associated with a marker of endothelial function and oxidative stress in patients with acute myocardial infarction

2016

Background Atrial fibrillation (AF), whether silent or symptomatic, is a frequent and severe complication of acute myocardial infarction (AMI). Asymmetric dimethylarginine (ADMA), an endogenous eNOS inhibitor, is a risk factor for endothelial dysfunction. We addressed the relationship between ADMA plasma levels and AF occurrence in AMI. Methods 273 patients hospitalized for AMI were included. Continuous electrocardiographic monitoring (CEM) ≥48 hours was recorded and ADMA was measured by High Performance Liquid Chromatography on admission blood sample. Results The incidence of silent and symptomatic AF was 39(14%) and 29 (11%), respectively. AF patients were markedly older than patients wit…

medicine.medical_specialty030204 cardiovascular system & hematologyPathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineHeart rateMedicine030212 general & internal medicineMyocardial infarctionRisk factorEndothelial dysfunctionComputingMilieux_MISCELLANEOUSEjection fractionbusiness.industryAtrial fibrillationEndothelial function[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseAtrial fibrillation3. Good healthMyocardial infarctionchemistryCardiologyCardiology and Cardiovascular MedicinebusinessAsymmetric dimethylarginine
researchProduct

0326: Prognostic factors and impact of blood pressure level during the first 48 hours after myocardial infarction

2016

Background High blood pressure and low blood pressure are perfectly identified cardio-vascular risk factors, especially in primary prevention. However, their respective role after myocardial infarction is uncertain, with few data available. Objectives To compare cardio-vascular deaths and events after myocardial infarction between the different blood pressure levels observed during the first forty-eight hours. Methods We carried out an observational, prospective, monocentric study, including all consecutive patients admitted in Dijon’s Cardiologic Intensive Care Unit for myocardial infarction, between February 2012 and February 2014. Systolic blood pressure (SBP) was defined as the average …

medicine.medical_specialtyAcute coronary syndromeEjection fractionbusiness.industryBlood pressure level[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognostic factorsmedicine.diseaseIntensive care unitlaw.inventionSurgeryMyocardial infarctionBlood pressurelawInternal medicineCardiologyMedicineObservational studycardiovascular diseasesMyocardial infarctionCardiology and Cardiovascular MedicinebusinessComputingMilieux_MISCELLANEOUSCardiovascular mortalityArchives of Cardiovascular Diseases Supplements
researchProduct

Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF

2020

Aims: \ud This retrospective analysis sought to identify markers that might distinguish between acute heart failure (HF) and worsening HF in chronic outpatients.\ud \ud Methods and Results: \ud The BIOSTAT‐CHF index cohort included 2516 patients with new or worsening HF symptoms: 1694 enrolled as inpatients (acute HF) and 822 as outpatients (worsening HF in chronic outpatients). A validation cohort included 935 inpatients and 803 outpatients. Multivariable models were developed in the index cohort using clinical characteristics, routine laboratory values, and proteomics data to examine which factors predict adverse outcomes in both conditions and to determine which factors differ between ac…

medicine.medical_specialtyAdverse outcomesacute heart failure treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemacute heart failure diagnosisInternal medicineOutpatientsDiagnosismedicineRetrospective analysisHumansAcute heart failure; acute heart failure diagnosis; acute heart failure treatmentRetrospective StudiesHeart Failurebusiness.industryTreatment developmentRoutine laboratoryAcute heart failurePrognosismedicine.diseaseR1[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHospitalizationTreatmentHeart failureChronic DiseaseCohortBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessCarbohydrate antigen
researchProduct